Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Nov 3 2025 | Bayer to Present New Data for KERENDIA® (finerenone) in People with Chronic Kidney Disease and Type 1 or Type 2 Diabetes at American Society of Nephrology (ASN) Kidney Week 2025 Industry News Industry Read More Oct 29 2025 | Impulse Dynamics Celebrates CMS National Coverage Determination for CCM Therapy Industry News Industry Read More Oct 23 2025 | Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025 Industry News Industry Read More Oct 10 2025 | Self-Reported Clinical HF Competencies of Advance Practice Nurses (APN) Read More Oct 1 2025 | Welcoming September's New HFSA Members HFSA News Membership Read More Pagination First page « First Previous page ‹ Previous … Page 9 Page 10 Page 11 Page 12 Current page 13 Page 14 Page 15 Page 16 Page 17 … Next page Next › Last page Last »
Nov 3 2025 | Bayer to Present New Data for KERENDIA® (finerenone) in People with Chronic Kidney Disease and Type 1 or Type 2 Diabetes at American Society of Nephrology (ASN) Kidney Week 2025 Industry News Industry Read More
Oct 29 2025 | Impulse Dynamics Celebrates CMS National Coverage Determination for CCM Therapy Industry News Industry Read More
Oct 23 2025 | Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025 Industry News Industry Read More
